Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Becotatug vedotin (MRG003) plus Pucotenlimab (HX008) in resectable oral cavity squamous cell carcinoma
ChiCTR2600130137Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and pucotenlimab in Oral Mucosal Carcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Major Pathological Response Rate (MPR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2600130137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130137.